Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

NCT ID: NCT00700622


Title
A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period
Purpose
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
Details
Conditions
Diabetes, Type 1
Keywords
Source
Mannkind Corporation
Sponsors
Mannkind Corporation
Status
Terminated
Acronym
Last Updated
08 Oct 2014
URL
Official Link
Locations
Brazil, United States